Your Search Results

Team approach to structural heart disease: how to handle unexpected situations

14 Feb 2026 – From PCR Tokyo Valves 2026

This session highlights the multidisciplinary team approach to managing structural heart disease, focusing on responses to unexpected intraoperative and postoperative situations. It features real-world experiences from a TAVI radiologic technologist, clinical engineer, TEER sonographer, and TEER nurse, emphasizing their respective roles in addressing intraoperative events, sudden...

Team approach to structural heart disease: how to handle unexpected situations

From diagnosis to device: decision-making and planning for mitral valve interventions

15 Feb 2026 – From PCR Tokyo Valves 2026

This session offers a structured approach to mitral TEER, integrating advanced imaging techniques for detailed mitral valve morphology evaluation, procedural planning, and complication prediction. It highlights device selection considerations and emerging technologies to tailor interventions for complex mitral valve disease, supported by multiple case presentations and...

From diagnosis to device: decision-making and planning for mitral valve interventions

Healthcare professionals in the structural heart disease treatment

15 Feb 2026 – From PCR Tokyo Valves 2026

This session highlights the essential roles and contributions of various healthcare professionals involved in structural heart disease treatment. It offers insights into the unique responsibilities of medical technologists, nurses, and radiological technologists across preoperative, intraoperative, and postoperative stages, fostering collaboration and sharing practical tips to strengthen...

Healthcare professionals in the structural heart disease treatment

Complications and bailout strategies in transcatheter mitral interventions

15 Feb 2026 – From PCR Tokyo Valves 2026

This session addresses complications arising during transcatheter mitral edge-to-edge repair (TEER), focusing on identification, anticipation, and management strategies. It also highlights the importance of case selection to improve procedural safety, supported by detailed case analyses covering leaflet/device, access/septal, and hemodynamic complications.

Complications and bailout strategies in transcatheter mitral interventions

Transcatheter electrosurgery and leaflet modification of the aortic valve

15 Feb 2026 – From PCR Tokyo Valves 2026

This session offers an expert overview of transcatheter electrosurgery and leaflet modification techniques for aortic valve interventions, focusing on TAV-in-SAV scenarios. It reviews patient selection, procedural setup, and material preparation, with detailed step-by-step guidance on BASILICA and UNICORN techniques, supported by recorded cases and troubleshooting strategies...

Transcatheter electrosurgery and leaflet modification of the aortic valve

TAVI: new evidence and clinical trials

14 Feb 2026 – From PCR Tokyo Valves 2026

This session reviews the latest evidence from head-to-head clinical trials comparing contemporary TAVI devices, including detailed discussions of the LANDMARK and COMPARE trials. It also highlights ongoing and upcoming clinical trials poised to influence guideline recommendations and expand the therapeutic scope of TAVI, providing crucial insights...

RIVER: Rivaroxaban for valvular heart disease and atrial fibrillation

05 Sep 2023

Alex Sticchi provides his take on the results of the RIVER trial, which were presented by Pedro Gabriel Barros E Silva during the ESC 2023 congress in Amsterdam.

Rivaroxaban versus Warfarin in Patients with Bioprosthetic Valves According to Valvular Heart Disease Etiology, and Thrombotic and Bleeding Risks: Insights from...

Author

Alessandro Sticchi

RIVER: Rivaroxaban for valvular heart disease and atrial fibrillation

SURTAVI: five-year results from a randomized trial of TAVR vs. SAVR in patients at intermediate surgical risk

07 Nov 2021

Although TAVI is an accepted alternative to surgery in patients with severe aortic stenosis who are at high surgical risk, less is known about long-term comparative outcomes among patients with aortic stenosis who are at intermediate surgical risk. P. Redaelli & M. Pighi review the SURTAVI trial...